The EIF4G3 Knockout A-549 Polyclonal Cells represent a polyclonal population of CRISPR/Cas9-edited A-549 human lung adenocarcinoma cells, engineered for loss-of-function studies of the EIF4G3 gene. This polyclonal knockout product avoids single-cell cloning, maintaining genetic heterogeneity while ensuring targeted gene disruption across the cell pool. The parental A-549 cell line is a widely recognized model for lung adenocarcinoma, providing a clinically relevant background for investigating translational control mechanisms in cancer.
A-549 cells were established from an explanted lung carcinoma and retain key features of alveolar epithelial cells, including expression of surfactant proteins. They harbor wild-type KRAS and exhibit anchorage-independent growth, making them a standard platform for oncogene addiction studies and drug response assays. In the knockout context, this host line supplies the appropriate molecular landscape to examine how EIF4G3-dependent translation influences malignant traits such as proliferation and metastasis.
EIF4G3 functions as an essential scaffold within the eIF4F translation initiation complex, bridging the mRNA cap-binding protein EIF4E and the DEAD-box RNA helicase EIF4A. This interaction facilitates recruitment of the 40S ribosomal subunit to the mRNA 5?? end, enabling cap-dependent scanning and translation initiation. EIF4G3 activity is modulated by the mTOR pathway: growth factor signaling activates mTOR, which phosphorylates 4E-BPs, freeing EIF4E to interact with EIF4G3. Additionally, EIF4G3 binds poly(A)-binding protein (PABP) to promote mRNA circularization. Consequently, knockout of EIF4G3 impairs cap-dependent translation, reducing synthesis of factors required for cell growth and division.
In A-549 cells, oncogenic mTOR signaling frequently drives elevated cap-dependent translation, contributing to uncontrolled proliferation. This EIF4G3 knockout model therefore permits dissection of the translation dependency of lung adenocarcinoma cells. Loss of EIF4G3 may selectively suppress translation of mRNAs with structured 5?? UTRs, many of which encode pro-oncogenic proteins. Researchers can use this system to probe the consequences of compromised eIF4F assembly on cell cycle progression, apoptosis, and metabolic reprogramming. The model also serves as a tool for evaluating the therapeutic potential of targeting the translation machinery in non-small cell lung cancer.
Typical applications include polysome profiling to analyze translation efficiency, cap-dependent reporter assays to quantify eIF4F function, and proliferation studies to assess growth defects. Western blotting and RT-qPCR confirm gene disruption and monitor downstream targets. The polyclonal nature of the knockout population allows detection of robust phenotypes without clonal artifacts. This product is suitable for screening chemical probes that target the translation initiation machinery and for genetic complementation experiments. For additional information or to request a custom derivative, please reach out to Ascent Research.
